Achieve 10-fold #exosome yields with AgentV™-DSP, a powerful downstream processing solution. This chemically defined reagent solves filtration problems by breaking up biological components in conditioned media to prevent filter fouling & particle loss. ➡️ https://t.co/EcSLiLnOtz

RoosterBio can help simplify a cellular therapeutic's path to the clinic by bypassing bottlenecks, reducing CMC risks, & saving months of time. This blog shows how getting the right "ducks in a row" can keep the focus on what matters most: the therapeutic. https://t.co/dAEUMnjsbL

RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01 - https://t.co/VZpoUt6FuP @RoosterBio @SecretomeTx

RoosterBio cells, media, and bioprocess tools help power clinical trials in actual human patients, and in this blog, we highlight 2 researchers who used such products to rapidly launch first-in-human studies for eye disease and post-COVID lung fibrosis.⤵️

🔍 AgentV™-Feed is a specialized bioreactor treatment specifically formulated to reduce microcarrier aggregation during upstream processing and maintain optimal MSC growth in high-yield cell culture. Learn more here->

📢 Join our webinar this Thursday hosted by @BioProcessOL to learn about scalable solutions and established processes that advanced therapy programs can utilize to address key challenges associated with clinical manufacturing. Learn more & Register here➡️ https://t.co/XsAIGQ6YhM

📰 RoosterBio and @SecretomeTx today announced completion of commercial-scale production of Secretome’s lead nCPC, STM-01, currently in clinical trials for the treatment of heart failure with preserved ejection fraction and dilated cardiomyopathy.⤵️ https://t.co/Euz3CI6vmv

RoosterBio and Secretome Therapeutics scaled production of STM-01, showing how progress in exosome manufacturing supports more efficient development of regenerative therapies for heart and neurological diseases. - @RoosterBio

Between scientific nomenclature, marketing shorthand and semantics, what exactly are we talking about when we say "exosome"? Transparency in nomenclature, sourcing and characterization is key to bridging semantics with real-world therapeutic translation.⤵️ https://t.co/MlrLTcNMF4

🗓️ Join RoosterBio on Thursday, Oct 9th for a webinar leveraging decades of experience to demonstrate scalable solutions and established processes that advanced therapy programs can utilize to address key challenges associated with clinical manufacturing.

📊 Biological components in conditioned media are a consistent problem during downstream processing of extracellular vesicles, resulting in significant EV loss at every step. Download this poster to learn how AgentV™-DSP can combat these challenges.⤵️

RoosterBio has developed a xeno-free hMSC bioreactor process that preserves cell integrity and yield across different bioreactor scales and seamlessly integrates into the @PBSBiotech Vertical-Wheel® bioreactor platform for a high-performance system.➡️ https://t.co/STnvZXT7B5

AgentV™-Feed is a specialized bioreactor treatment formulated to reduce microcarrier aggregation & maintain optimal MSC growth in suspension for extended culture times, enabling higher cell densities for increased MSC and exosome yields. Learn more⤵️

📙 With ISEV & ISCT 2025 in the rear-view mirror, RoosterBio's delegation sat down to discuss what we carried forward from these conferences and how those insights will shape the path ahead for cell and gene therapies. Read about it in our latest blog.⤵️ https://t.co/u6GY3YwcQd

AgentV™-DSP is a drop-in formulation that significantly improves production yields of extracellular vesicles by preventing filter fouling and increasing filter capacity to boost particle recovery. Learn how it economizes the downstream process here⤵️ https://t.co/xCbZs9hK6B

To maximize therapeutic potential, extracellular vesicles need established quality attributes. This webinar explores how analytical tools can assess the impact of production process choices and tissue source on the quality attributes of MSC-derived EVs. ▶️ https://t.co/gvQEHVumsU

📊 Biological components in conditioned media are a consistent problem during downstream processing of EVs, blocking filters and causing significant EV loss at every step. AgentV™-DSP prevents these issues while maintaining critical quality attributes.

The Scalable Solution for 10X Exosome Yield: AgentV-DSP AgentV™-DSP, a solution from @RoosterBio, is designed to prevent filter fouling and deliver novel processing advantages, including greater filter loading capacity and higher #exosome yield. https://t.co/Cs7EaHgomT

This collaborative study between RoosterBio & @BioSpherix shows that the oxygen microenvironment profoundly affects the miRNA cargo of MSC-EVs. Its findings support oxygen tuning as a critical lever for optimizing EV therapeutic potency. Download it here⤵️

AgentV™-DSP is helping "change the tune" for cell therapies and bioproduction, offering 10X greater efficiency for exosome manufacturing. Read how this downstream processing treatment can significantly improve exosome yield while maintaining quality. ➡️  https://t.co/rujQSTZcXI

Publication Spotlight! 💡 Remove the uncertainty from your scale-up and differentiation process development with this MSC, MSC-EV scale-up protocol. @RoosterBio Read the FULL publication here: https://t.co/5xLPPm8phk #PBSBiotech #MSCs #EVs #ScaleUp #Bioprocess